Clinical Trial

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Name: Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients — clinical trial record (NCT07358520)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.

Trial Details

NCT Number	NCT07358520
Lead Sponsor	Fudan University
Conditions	Proteinuria
Enrollment	40 participants
Start Date	2026-01-28
Primary Completion	2027-01-28 (estimated)
Study Completion	2028-01-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-22